Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine

McFarland, Robert; Bateson, M C; Green, J.R.B.; O’Donoghue, Diarmuid; Dronfield, M W; Keeling, P. W. N.; Burke, G; Dickinson, Rebecca; Shreeve, David R; Peers, Elizabeth; Richardson, Paul

doi:10.1016/0016-5085(90)90815-i

Cited by 68 publications

(24 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Others (8-10) reported omeprazole use for 8 to 12 weeks (20-40 mg/day) and no clinically important changes were observed in the serologic and hematologic laboratory results. In this study, there were no adverse effects on liver function tests after treatment, con rming previous work showing that elevation of transaminases occurred in only 1% to 2% of patients after omeprazole treatment and usually after doses greater than 40 mg/day (11)(12)(13)(14). In general, omeprazole was excellent for symptomatic relief, especially relief of pain in patients with DU.…”

Section: Discussionsupporting

confidence: 88%

Low Incidence of Helicobacter pylori Infection in Patients with Duodenal Ulcer and Chronic Liver Disease

Shahin¹,

Abdel-Baset²,

Nassar³

et al. 2001

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 88%

Low Incidence of Helicobacter pylori Infection in Patients with Duodenal Ulcer and Chronic Liver Disease

Shahin¹,

Abdel-Baset²,

Nassar³

et al. 2001

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…It has also been shown that LP protects against ethanol‐induced ulcer formation 25 4 and a protector against AE‐induced ulcer formation 8 14,25 were also found to protect against AE‐induced gastric haemorrhagic lesions, indicating that the antisecretory and anti‐ulcer activities go in parallel.…”

Section: Discussionmentioning

confidence: 94%

“…The antisecretory potency of LP in dogs is similar to OP and approximately half that of ranitidine, but, in rats, at least, its potency has been shown to be twice that of OP and 14–16‐fold that of ranitidine 5 6 the PPI are considered to be more potent antisecretory agents than histamine H 2 receptor antagonists, with a longer duration of action and greater capacity to induce more ulcer healing 8 …”

Section: Introductionmentioning

confidence: 99%

“…We have also demonstrated that PD selectively inhibits gastrin‐stimulated acid secretion, increases bicarbonate secretion and displays anxiolytic properties 16,17 18,19 and PPI 8 are involved in the maintenance of gastrointestinal mucosal integrity, the mechanisms of their protective effects are not fully understood. Therefore, the objectives of the present study were twofold: (i) to study the effect of PD on gastric ulcers induced by acidified ethanol (AE) and indomethacin and compare the results obtained with those of the PPI; and (ii) to determine the possible involvement of endogenous prostaglandins (PG) and nitric oxide (NO) in the cytoprotective action of LP, OP and PD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Comparative Study On The Activity Of Lansoprazole, Omeprazole And PD‐136450 On Acidified Ethanol‐ And Indomethacin‐Induced Gastric Lesions In The Rat

Chandranath

Bastaki

Singh

2002

Clin Exp Pharma Physio

View full text Add to dashboard Cite

1. The proton pump inhibitors lansoprazole (LP) and omeprazole (OP) and the cholecystokinin (CCK)-receptor antagonist PD-136450 (PD) provide a broad spectrum of activities in their ability to inhibit gastric acid secretion and protect the stomach against ulcerogens. In the present study, we investigated the protective effects of these compounds against gastric ulcers induced by acidified ethanol (AE) and indomethacin. 2. Both AE (60% ethanol in 150 mmol/L HCl, 1 mL/rat) and indomethacin (30 mg/kg) produced gastric haemorrhagic lesions in the rat 1 and 6 h after oral administration, respectively. 3. The gastric mucosal protective effects of LP (1-20 mg/kg), OP (0.5-10 mg/kg) and PD (1-20 mg/kg), administered either orally or subcutaneously (s.c.) 30 min before the administration of AE or indomethacin, were dose dependent against both models of ulcer induction. 4. To determine whether the cytoprotective effect of LP, OP and PD (each 10 mg/kg) was mediated by endogenous prostaglandins (PG), indomethacin (10 mg/kg, s.c.) was administered 15 min before AE to inhibit prostanoids biosynthesis. Indomethacin reduced the cytoprotective effects of OP, but not LP, administered either orally or s.c. Indomethacin reduced the cytoprotective effect of PD administered orally, although the effect was much less significant than when PD was administered s.c. The results exclude the role of PG in mediating the protective effects of LP, whereas the possibility exists for PG to have a role in mediating the protective effects of OP and PD. 5. To investigate the possible involvement of endogenous nitric oxide (NO) in the cytoprotective action of LP, OP and PD, we treated rats with a selective inhibitor of NO synthesis, namely NG-nitro-L-arginine methyl ester (L-NAME; 25 mg/kg, s.c.). Administration of L-NAME 15 min prior to LP, OP or PD (each 10 mg/kg) orally or s.c. and challenge with AE or indomethacin did not significantly increase the degree of the ulcer index and L-NAME was not able to antagonize the protective effects of LP, OP and PD, thus excluding the role of NO in mediating the protective effects of these drugs. However, the effects of PD in reducing the indomethacin-induced ulcer index were less significant in the presence than the absence of L-NAME (P < 0.05 vs P < 0.001, respectively), suggesting a role for NO. 6. In conclusion, the results of the present study suggest that LP and OP are equally effective against AE- as well as indomethacin-induced gastric ulcers and were more potent than PD in protecting the stomach against ulcer formation. Lansoprazole, OP and PD bring about their cytoprotective action through the reduction of acid secretion and some other unknown mechanisms. However, OP and PD may exert their cytoprotective action through PG and NO pathways.

show abstract

“…[1][2][3] . Used in the treatment of peptic ulcers, [4,5] reflux oesophagitis, [6] and the Zollinger-Ellison syndrome, [7,8] omeprazole is a lipophilic, weak base with pKa1 = 4.2 and PKa2 = 9 and is subject to degradation processes, unless protected against acidic conditions. [2] The number of its decomposition products have been elucidated and characterized by Brändström et al under different conditions.…”

Section: Introductionmentioning

confidence: 99%

Spectrophotometric and chromatographic determination of omeprazole in pharmaceutical formulations

Gallardo

López-Viota

Sierra

et al. 2009

Pharmaceutical Development and Technology

View full text Add to dashboard Cite

The purpose of this study was to determine the stability of the pH sensitive drug, omeprazole, within different solid oral pharmaceutical formulations and to determine whether the addition of antacid and surfactant agents, at varying concentrations, influenced drug stability and release. Spectrophotometric and chromatographic techniques were used for evaluation purposes, giving good results concerning linearity, precision and specificity within the range of concentrations used in this study. However, the results show that the degradation products of omeprazole interfere with spectrophotometric evaluation, making this technique insufficiently selective for omeprazole. On the other hand, liquid chromotography proved to be more sensitive, accurate and precise. Additionally, in an attempt to improve the administration form of the drug, an extemporaneous suspension was designed, which after evaluation proved to be a satisfactory administration vehicle. The best formulation of omeprazole studied is: omeprazole: 0.5%; corn starch 34.2%; aluminum hydroxide 26%; magnesium hydroxide 13%; simple syrup 24.8%; SDS 1%.

show abstract

Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine

Cited by 68 publications

References 8 publications

Low Incidence of Helicobacter pylori Infection in Patients with Duodenal Ulcer and Chronic Liver Disease

Low Incidence of Helicobacter pylori Infection in Patients with Duodenal Ulcer and Chronic Liver Disease

A Comparative Study On The Activity Of Lansoprazole, Omeprazole And PD‐136450 On Acidified Ethanol‐ And Indomethacin‐Induced Gastric Lesions In The Rat

Spectrophotometric and chromatographic determination of omeprazole in pharmaceutical formulations

Contact Info

Product

Resources

About